Aesthetic
CO2 Products
CO2 lasers are intended solely for use by physicians trained in the use of the Carbon Dioxide laser (10.6 μm) wavelength. Incorrect treatment settings or misuse of the technology can present risk of serious injury to patient and operating personnel. Risks that may be associated with any CO2 laser procedure may include change of pigmentation, infection, erythema, skin induration or scarring. Read and understand the CO2 systems and accessories operator manuals for a complete list of intended use, contraindications and risks. The use of Lumenis CO2 laser is contraindicated where a patient has taken Accutane (Isotretinoin) within the past 6-12 months, has a history of keloid formation and demonstrate excessive or unusually prolonged erythema.
M22
M22 is contraindicated for patients with active infection, viral, fungal or bacterial diseases. The use of M22 could cause redness, swelling, scarring, change of pigmentation. See the system user manual for a complete list of contraindications and risks.
LightSheer
Treatment should not be attempted on patients with the following conditions in the treatment area: any active infections or inflammatory skin conditions, Dysplastic nevi, tattoos, active cold sores, open lacerations or abrasions, viral, fungal, or bacterial diseases or a history of post inflammatory hyperpigmentation. The most common immediate responses of laser treatment for hair removal, vascular lesions, pigmented lesions are erythema, edema, perifollicular edema and perivascular edema, vascular bleaching, hyperpigmentation and hypopigmentation or textural changes of the treated areas. The complete list of contraindications and risks can be found in the LigthSheer system user manual.
Ophthalmology
Retina Family
Lumenis photocoagulators and delivery devices are intended solely for use by trained physicians. It is contraindicated for eyes with severe media opacities. Risks include increased macular edema and bleeding in areas of neovascularization. Refer to the operator manual for a complete list of intended use, contraindications and risks.
Retina Products
Smart 532/ Spectra/ Array/ Vision One is intended solely for use by trained physicians. It is contraindicated for eyes with severe media opacities. Risks include increased macular edema and bleeding in areas of neovascularization. Refer to the operator manual for a complete list of intended use, contraindications and risks.
Glaucoma Family
SLT: Lumenis SLT devices are intended solely for use by trained physicians. It is contraindicated for eyes with neovascular or angle-closure glaucoma. Risks include iritis, conjunctivitis and IOP rise. Refer to the operator manual for a complete list of intended use, contraindications and risks.
YAG: Lumenis YAG devices are intended solely for use by trained physicians. It is contraindicated for eyes with corneal pathologies and chronically elevated IOP. Risks include IOP rise, macular edema and retinal detachment. Refer to the operator manual for a complete list of intended use, contraindications and risks.
Glaucoma Products
Selecta II
Selecta II is intended solely for use by trained physicians. It is contraindicated for eyes with neovascular or angle-closure glaucoma. Risks include iritis, conjunctivitis and IOP rise. Refer to the operator manual for a complete list of intended use, contraindications and risks.
Smart Selecta Duet
Selecta Duet is intended solely for use by trained physicians. SLT: contraindicated for eyes with neovascular or angle-closure glaucoma. Risks include iritis, conjunctivitis and IOP rise. YAG: contraindicated for eyes with corneal pathologies and chronically elevated IOP. Risks include IOP rise, macular edema and retinal detachment. Refer to the operator manual for a complete list of intended use, contraindications and risks.
Smart Selecta Trio
Smart Selecta Trio is intended solely for use by trained physicians. SLT: contraindicated for eyes with neovascular or angle-closure glaucoma. Risks include iritis, conjunctivitis and IOP rise. YAG: contraindicated for eyes with corneal pathologies and chronically elevated IOP. Risks include IOP rise, macular edema and retinal detachment. Smart 532: contraindicated for eyes with severe media opacities. Risks include increased macular edema and bleeding in areas of neovascularization. Refer to the operator manual for a complete list of intended use, contraindications and risks.
M22
M22 is contraindicated for patients with active infections, dysplatic nevi, or tattoos in the treatment area. Risks include redness, swelling, scarring, and change of pigmentation. Refer to the operator manual for a complete list of intended use, contraindications and risks.